|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Nalm 1 Human cell line|
|Conjugate||Alexa Fluor® 488|
|Storage buffer||PBS with 4mg/ml BSA|
|Contains||0.1% sodium azide|
|Storage Conditions||4° C, store in dark|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||Assay-Dependent|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Flow Cytometry (Flow)||See 2 publications below|
Based on our testing, publications, and results reported from customers, the Alexa Fluor® 488 dye provides the best fluorescein (FITC) substitute.
CD19 is a member of the immunoglobulin superfamily and has two Ig like domains. The CD19 molecule is expressed on 100% of the peripheral B cells as defined by expression of kappa or lamda light chains. It appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation. It is expressed in all B cell precursor leukemias.
Analyte Specific Reagent
Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis.
MHCD1920 was used in flow cytometry report the results of the rituximab by intravenous and Intrathecai injection versus placebo in patients with low-inflammatory secondary progressive multiple sclerosis study
|Komori M,Lin YC,Cortese I,Blake A,Ohayon J,Cherup J,Maric D,Kosa P,Wu T,Bielekova B||Annals of clinical and translational neurology (3:166)||2016|
Expression of B-cell surface antigens in subpopulations of exosomes released from B-cell lymphoma cells.
MHCD1920 was used in flow cytometry to characterize CD81(+) and CD63(+) subpopulations of exosomes released from B-cell lymphoma cell lines
|Oksvold MP,Kullmann A,Forfang L,Kierulf B,Li M,Brech A,Vlassov AV,Smeland EB,Neurauter A,Pedersen KW||Clinical therapeutics (36:847)||2014|